Under the conditions, the firms shall submit data of ongoing clinical trials and the vaccines to be supplied for programmatic setting.Adverse event following immunisation will continue to be monitored.
India achieved this coverage in 130 days as against the USA's feat in 124 days.
The Centre has shared a set of parameters with all states and UTs to enable service providers and monitoring teams under the national COVID-19 vaccination programme to identify any fake COVID-19 vaccines so that they are not administered in the country.
SII said it will address the limited capacity by scaling up the vaccine production over the next two months.
As India prepares to launch its vaccine drive on January 16, here is a look at the options:
There were apprehensions in the SII about rival Bharat Biotech's 'indigenous' tag, opening up shortcuts for it. One senior person, who was very familiar with the sector, told me, 'The message has gone out from the very top. Somani (V G Somani -- drug controller general of India) has told me "Bharat ka karna hai".' A fascinating excerpt from Abantika Ghosh's Billions Under Lockdown: The Inside Story Of India's Fight Against COVID-19.
'We are hoping by March, the government allows us to export and give it to the private market.'
'The immune protection may well wane somewhat, and that's what we have to monitor.' 'Should it wane to the point where vaccinated individuals are getting severe disease, then we really will need to give them booster shots and that'll apply regardless of what vaccine they've got the first time.'
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances